Unproven, dangerous cancer medicine got go-ahead from FDA

Print Friendly, PDF & Email
Afinitor

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.

Walking the beaches around Los Angeles where she lives was one of life’s pleasures for Susan Preston-Martin, a retired university professor and breast cancer patient.

That pleasure was interrupted when she began taking Afinitor (everolimus) to treat her breast cancer.

Just getting out of bed and taking a shower in the morning was difficult. Walks along the shore were impossible. She felt so bad she gave her pills, which cost $450 each, back to the pharmacy.

She didn’t know that the FDA approved everolimus without proof that it extended life.

Indeed, despite that lack of proof, the drug has come before the FDA five times in the last six years, and each time won approval for a new indication. Everolimus is now used to treat advanced breast and kidney cancer, a rare type of pancreatic cancer, and two types of nonmalignant tumors.

But in the desperate world of cancer medicine, toxic and expensive drugs that aren’t proven to extend life can quickly achieve blockbuster status.

For everolimus, each FDA approval for a new condition increased the pool of potential patients — and potential sales — for the drug, sometimes substantially.

Among cancer drugs, everolimus stands out for its repeated approvals despite what independent doctors say are serious concerns — particularly for breast cancer patients.

Read full, original post: Slippery Slope: A Targeted Therapy That Misses The Mark?

Outbreak Daily Digest
Biotech Facts & Fallacies
GLP Podcasts
Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

Infographic: Trending green and going great — Every state in the US seeing decreased cases of COVID

The U.S. averaged fewer than 40,000 new cases per day over the past week. That’s a 21% improvement over the ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
glp menu logo outlined

Newsletter Subscription

* indicates required
Email Lists